Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate
Adaptive Biotechnologies Q1 2024 GAAP EPS $(0.33) Beats $(0.35) Estimate, Sales $41.873M Beat $38.784M Estimate
自適應生物技術公司2024年第一季度GAAP每股收益美元（0.33美元）超過預期（0.35美元），銷售額4187.3萬美元超過預期的3,8784萬美元
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 17.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $41.873 million which beat the analyst consensus estimate of $38.784 million by 7.96 percent. This is a 11.23 percent increase over sales of $37.647 million the same period last year.
自適應生物技術（納斯達克股票代碼：ADPT）公佈的季度虧損爲每股0.33美元，比分析師普遍預期的0.35美元（0.35美元）高出5.71％。這比去年同期每股虧損0.40美元（0.40）增長了17.5％。該公司公佈的季度銷售額爲4187.3萬美元，比分析師普遍預期的3878.4萬美元高出7.96％。這比去年同期的3764.7萬美元的銷售額增長了11.23％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。